Brian P Kearney
Overview
Explore the profile of Brian P Kearney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1867
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jin B, W Gongwer M, Kearney B, Ohanian L, Holden-Wingate L, Le B, et al.
bioRxiv
. 2024 Jan;
PMID: 38260633
Memories formed early in life are short-lived while those formed later persist. Recent work revealed that infant memories are stored in a latent state. But why they fail to be...
2.
Yang Z, Wong S, Cha D, Wilfret D, Turnquist D, Plummer A, et al.
Drug Metab Dispos
. 2023 Sep;
51(12):1607-1614.
PMID: 37684056
Pomotrelvir is an orally bioavailable, target antiviral inhibitor of the main protease (M) of coronaviruses, including severe acute respiratory syndrome coronavirus 2, the etiological agent of Coronavirus Disease 2019. The...
3.
Yang Z, Rioux N, Vincent L, Jones H, Cha D, Plummer A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Aug;
12(10):1553-1564.
PMID: 37614073
Pomotrelvir is a new chemical entity and potent direct-acting antiviral inhibitor of the main protease of coronaviruses. Here the cytochrome P450 (CYP)-mediated drug-drug interaction (DDI) potential of pomotrelvir was evaluated...
4.
Meng A, Anderson K, Nelson C, Ni L, Chuang S, Bellanti F, et al.
Br J Clin Pharmacol
. 2022 Jan;
88(7):3211-3221.
PMID: 35072287
Aims: Filgotinib is a potent, oral, JAK1-preferential inhibitor for the treatment of rheumatoid arthritis (RA). This report describes exposure-response (ER) analyses of filgotinib for dose confirmation based on three phase...
5.
Kirby B, Lutz J, Yue M, Garrison K, Qin A, Ampaw L, et al.
Clin Pharmacol Ther
. 2020 Nov;
109(5):1334-1341.
PMID: 33141923
Firsocostat (FIR: previously GS-0976), a highly sensitive OATP substrate, reduces hepatic de novo lipogenesis (DNL) by inhibiting acetyl-CoA carboxylases (ACC). Measuring the pharmacodynamic (PD) efficacy of FIR on DNL provides...
6.
Begley R, Anderson K, Watkins T, Weng W, Ampaw L, Qin A, et al.
Clin Pharmacol Drug Dev
. 2020 Sep;
10(4):376-383.
PMID: 32989920
Filgotinib (FIL) is a potent and selective JAK1 inhibitor in clinical development for treatment of severe inflammatory diseases. A drug-drug interaction study to evaluate the potential effect of FIL on...
7.
Xiao D, Ling K, Tarnowski T, Majeed S, German P, Kearney B, et al.
Anal Biochem
. 2020 Feb;
593:113611.
PMID: 32035040
Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are both tenofovir (TFV) prodrugs, with the same active intracellular metabolite, TFV-diphosphate (TFV-DP). TAF delivers TFV-DP to target cells more efficiently and...
8.
Majeed S, West S, Ling K, Das M, Kearney B
Antivir Ther
. 2020 Jan;
24(8):557-566.
PMID: 31933482
Background: Cobicistat (COBI), a CYP3A inhibitor, is a pharmacokinetic enhancer that increases exposures of the HIV protease inhibitors (PIs) atazanavir (ATV) and darunavir (DRV). The potential drug interaction between COBI-boosted...
9.
Anderson K, Xin Y, Zheng H, Yun C, Kwan E, Qin A, et al.
Clin Pharmacol Drug Dev
. 2019 Dec;
9(1):32-40.
PMID: 31797578
Filgotinib, a selective inhibitor of Janus kinase 1, is being developed for the treatment of chronic inflammatory diseases. Electrocardiograms evaluated the effect of filgotinib on the corrected QT (QTc) interval...
10.
Begley R, Das M, Zhong L, Ling J, Kearney B, Custodio J
J Acquir Immune Defic Syndr
. 2018 Apr;
78(4):465-472.
PMID: 29649076
Background: Tenofovir alafenamide (TAF), a prodrug of the nucleotide analogue tenofovir (TFV), is an antiretroviral (ARV) agent approved either as a complete regimen [elvitegravir/cobicistat/emtricitabine (F)/TAF, rilpivirine/F/TAF, bictegravir/F/TAF], or for use...